CSS
NKGN

Cubist Systematic Strategies’s NKGen Biotech, Inc. Common Stock NKGN Stock Holding History

Cubist Systematic Strategies’s Portfolio NKGN Stock Details NKGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-505,206
Closed -$5.12M – 4436
2023
Q1 		$5.12M Sell
505,206
-10,400
-2% -$105K 0.03% 910
2022
Q4 		$5.13M Buy
515,606
+7,943
+2% +$78.5K 0.03% 996
2022
Q3 		$4.95M Buy
507,663
+7,196
+1% +$70.2K 0.03% 1081
2022
Q2 		$4.86M Buy
500,467
+332,492
+198% +$3.23M 0.03% 1017
2022
Q1 		$1.63M Sell
167,975
-6,530
-4% -$63.3K 0.01% 1658
2021
Q4 		$1.69M Buy
+174,505
New +$1.7M 0.02% 1516

Other funds holding NKGN

RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
FTCM
Fir Tree Capital Management New York $21.8M AUM 1.61% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2B AUM 0.66% 1-Year Est. Return
SIM
Sandia Investment Management Boston, Massachusetts $40.1M AUM 14.58% 1-Year Est. Return
SFM
Spartan Fund Management Toronto, Ontario, Canada $30M AUM 11.98% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return

Cubist Systematic Strategies's NKGN Position: Q2 2023 in Review

Cubist Systematic Strategies sold out of NKGen Biotech, Inc. Common Stock (NKGN) in Q2 2023, closing a stake of 505,206 shares — an estimated $5.12M sold.

Cubist Systematic Strategies first reported a position in NKGN in Q4 2021 and held it in 6 quarters. The position peaked at $5.13M in Q4 2022. 25 funds tracked by Wall St. Rank hold NKGN as of Q2 2023.

  • Cubist Systematic Strategies reported no remaining NKGen Biotech, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Cubist Systematic Strategies sold 505,206 NKGen Biotech, Inc. Common Stock shares in Q2 2023, an estimated $5.12M.
  • Cubist Systematic Strategies first reported a position in NKGen Biotech, Inc. Common Stock in Q4 2021 and held it in 6 quarters.
  • Cubist Systematic Strategies's NKGen Biotech, Inc. Common Stock position peaked at $5.13M in Q4 2022.
  • 25 funds tracked by Wall St. Rank held NKGen Biotech, Inc. Common Stock as of Q2 2023.

Based on Cubist Systematic Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.